Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the phase IIb evaluation of fosdevirine (GSK2248761)

Antiviral Therapy

Volumn 19, Issue 1, 2014, Pages 69-78

  Margolis, David A ^a   Eron, Joseph J ^b   DeJesus, Edwin ^c   White, Scott ^a   Wannamaker, Paul ^a   Stancil, Britt ^a   Johnson, Mark ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSDEVIRINE; RALTEGRAVIR; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NIGHTMARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-HIV AGENTS; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDOLES; MALE; PHOSPHINIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; SEIZURES; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84896939947     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2689     Document Type: Article

References (28)

1. Richman DD, Jakubik J, Chapron C, et al. Genotypic resistance and phenotypic cross-resistance profile in vitro for a novel NNRTI: IDX899. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Poster 729.
2. Zhou X-J, Pietropaolo K, Damphousse D, et al. Single dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2009; 53:1739-1746.
3. Piscitelli S, Kim J, Gould E, et al. Drug interaction profile for GSK2248761, a next-generation non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol 2012; 74:336-345.
4. Zala C, St Clair M, Dudas K, et al. Safety and efficacy of GSK2248761, a next-generation non-nucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects. Antimicrob Agents Chemother 2012; 56:2570-2575.
5. Beghi E, Monticelli ML, Monza G, et al. Antiepileptic drugs as 'tracers' of disease. A calculation of the prevalence of epilepsy through an analysis of drug consumption. Neuroepidemiology 1991; 10:33-41.
6. Bielen I, Cvitanovic-Sojat L, Bergman-Markovic B, et al. Prevalence of epilepsy in Croatia: a population-based survey. Acta Neurol Scand 2007; 116:361-367. (Pubitemid 350045496)
7. Gallitto G, Serra S, La Spina P, et al. Prevalence and characteristics of epilepsy in the Aeolian islands. Epilepsia 2005; 46:1828-1835. (Pubitemid 44921969)
8. Giuliani G, Terziani S, Senigaglia AR, et al. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol Scand 1992; 85:23-31.
9. Maremmani C, Rossi G, Bonuccelli U, et al. Descriptive epidemiologic study of epilepsy syndromes in a district of northwest Tuscany, Italy. Epilepsia 1991; 32:294-298.
10. Olafsson E, Hauser WA. Prevalence of epilepsy in rural Iceland: a population-based study. Epilepsia 1999; 40:1529-1534. (Pubitemid 29518081)
11. Rocca WA, Savettieri G, Anderson DW, et al. Door-to-door prevalence survey of epilepsy in three Sicilian municipalities. Neuroepidemiology 2001; 20:237-241. (Pubitemid 34701952)
12. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991; 32:429-445.
13. Holden EW, Thanh Nguyen H, Grossman E, et al. Estimating prevalence, incidence, and disease-related mortality for patients with epilepsy in managed care organizations. Epilepsia 2005; 46:311-319. (Pubitemid 40194676)
14. Kotsopoulos IA, van Merode T, Kessels FG, et al. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002; 43:1402-1409. (Pubitemid 35365000)
15. Chadha DS, Handa A, Sharma SK, et al. Seizures in patients with human immunodeficiency virus infection. J Assoc Physicians India 2000; 48:573-576.
16. Kellinghaus C, Engbring C, Kovac S, et al. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure 2008; 17:27-33. (Pubitemid 350256998)
17. Pascual-Sedano B, Iranzo A, Marti-Fàbregas J, et al. Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. Arch Neurol 1999; 56:609-612. (Pubitemid 29218157)
18. Wong MC, Suite ND, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol 1990; 47:640-642. (Pubitemid 20183570)
19. Norvir (ritonavir). Package insert 2012. Abbott Laboratories, North Chicago, IL, USA.
20. Viracept (nelfinavir). Package insert 2012. ViiV Healthcare, Research Triangle Park, NC, USA.
21. Invirase (saquinavir). Package insert 2012. Genentech USA, Inc., South San Francisco, CA, USA.
22. Selzentry (maraviroc). Package insert 2011. ViiV Healthcare, Research Triangle Park, NC, USA.
23. Retrovir (zidovudine). Package insert 2012. ViiV Healthcare, Research Triangle Park, NC, USA.
24. Intelence (etravirine). Package insert 2012. Janssen Therapeutics, Titusville, NJ, USA.
25. Sustiva (efavirenz). Package insert 2011. Bristol-Myers Squibb Co., Princeton, NJ, USA.
26. Ivey NS, MacLean AG, Lackner AA. AIDS and the bloodbrain barrier. J Neurovirol 2009; 15:111-122.
27. Strazza M, Pirrone V, Wigdahl B, et al. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011; 1399:96-115.
28. Castellino S, Groseclose MR, Sigafoos J, et al. Central nervous system disposition and metabolism of fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: an LC-MS and matrix-assisted laser desorption/ionization imaging MS investigation into central nervous system toxicity. Chem Res Toxicol 2013; 26:241-251.